Project Grant R03AG083702

Award Date 5/1/24
Completion Date 4/30/26
Dollars Obligated $305K
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This three-year, $3.24 million project grant from the National Institutes of Health National Institute on Aging will fund research into the role of clusterin in oligodendrocyte lineage and myelination in Alzheimer's disease. Specifically, the University of Virginia researchers will pursue three aims: 1) determine the mechanisms of clusterin expression and its inhibition of oligodendrocyte progenitor cell differentiation; 2) assess the impact of pathological clusterin expression on myelination,...
This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $4,638,424 to the University of California, San Diego from August 1, 2022 to July 31, 2025. The grant will support research developing novel quantitative magnetic resonance imaging techniques to directly image myelin and quantify myelin content and properties in the brain. Specifically, the researchers will use ultra-short echo time sequences with echo...
This $481,250 Project Grant was awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to Vanderbilt University Medical Center (VUMC) on September 1, 2024. The award supports the development of an innovative, non-invasive MRI imaging technique to assess membrane lipid properties in Alzheimer's disease (AD). The key objectives are to: 1) verify the relationship between the MRI nuclear Overhauser enhancement (NOE) signal and lipid properties using reconstituted phospholipid...
This $4.49 million project grant from the National Institutes of Health's National Institute on Aging will fund research at The Washington University to investigate the relationship between amyloid plaque deposition, cellular metabolic dysfunction, and functional brain organization in Alzheimer's disease (AD) mice models. Over three years, the researchers will use multi-photon fluorescence lifetime imaging microscopy, multi-parametric photoacoustic microscopy, and wide-field optical imaging to...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), provides $328,000 to an interdisciplinary research team at the University of California, San Francisco (UCSF) to conduct a pilot study titled "Alzheimer's Disease Organelle Proteome Task (ADOPT) - Pilot Phase." The project aims to quantitatively measure the organelle proteome, including protein abundance, post-translational modifications, and protein...
This Project Grant award of $837,500 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research to characterize and validate the use of the PET radiotracer [18F]3F4AP for detecting and quantifying demyelination and cerebral perfusion in Alzheimer's disease (AD), mild cognitive impairment (MCI), and cognitively normal individuals. The research will perform the first full pharmacokinetic evaluation of this tracer in human subjects with AD and MCI, and validate...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $795,542 to the University of California, Davis to study lipid mediator pathways involved in neuronal survival and repair in Alzheimer's disease (AD). The key goals are to understand whether neuronal loss in AD is caused by deficits in the supply of free "pro-repair" lipid mediators from brain lipid pools, and to test whether replenishing these lipid mediator pools can provide...
This $107,948 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to enhance understanding of the biological signatures that distinguish subgroups of patients with Alzheimer's disease (AD). The key goals are to: Determine if AD subtypes can be identified solely using magnetic resonance imaging (MRI)-derived features through the application of machine learning algorithms. Integrate epigenetic profiles, including small non-coding RNA expression and DNA...
This $3.6 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, will fund research at the Icahn School of Medicine at Mount Sinai directed at understanding the role of glial cell interactions surrounding amyloid plaques in the progression of Alzheimer's disease. As part of the Aging Research program (CFDA 93.866), the three-year award will support investigation of how deletion of the Plexin-B1 gene impacts glial network formation and the...
This $342,934.65 project grant from the Department of Health and Human Services National Institutes of Health National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research into acyl chain remodeling and regional lipid dysregulation in Alzheimer's disease. The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, will analyze lipid composition in brain regions susceptible to Alzheimer's disease, such as the...

QUANTIFYING MYELIN DEGENERATION IN AD - PROJECT SUMMARY/ABSTRACT MYELIN IS THE INSULATING SHEATH AROUND NEURONAL AXONS (CONSISTING OF 25% PROTEINS/75% LIPIDS) THAT FACILITATES FAST AND EFFICIENT SIGNAL TRANSDUCTION. IN THE RECENT YEARS, ITS PLASTICITY HAS BEEN SHOWN TO BE KEY FOR COGNITION, MEMORY FORMATION AND CONSOLIDATION. ALZHEIMER'S DISEASE (AD) DEBILITATES COGNITION AND MEMORY, WITH AMYLOID AND TAU BEING HALLMARKS OF THE DISEASE, YET ITS ONSET AND PROGRESSION MECHANISMS REMAIN UNRESOLVED. RECENT EVIDENCE FROM IMAGING, PROTEOMICS, AND GENOMICS SUPPORT MYELIN'S INVOLVEMENT IN AD, AS WELL AS INTERACTIONS WITH AMYLOID, TAU, AND NEUROINFLAMMATION. YET MYELIN'S ROLE, PATTERN OF DEGENERATION, AND INTERPLAY WITH AD PA- THOLOGY REMAIN UNKNOWN. A LIMITING FACTOR HAS BEEN THE LACK OF MYELIN STUDIES INTEGRATING DIFFERENT SCALES: A MA- CROSCOPIC MYELIN IMAGING METHOD WITH TARGETED MOLECULAR PROFILING AND CORRELATIONS WITH KNOWN AD PATHOLOGIES. WE AIM TO ADDRESS THIS IMPORTANT KNOWLEDGE GAP BY COMBINING THREE INNOVATIVE APPROACHES. FIRST, OUR NOVEL SYNCHROTRON X-RAY IMAGING (SAXS-TT) THAT IS SPECIFIC TO MYELIN DUE TO PHOTONS DIFFRACTING OFF THE PERIODIC MYELIN SHEATH AND PROVIDES QUANTITATIVE 3D MAPS OF MYELIN LEVELS AND INTEGRITY. SECOND, OUR DETAILED 3D IMAG- ING-HISTOLOGY REGISTRATION PIPELINE, WHICH ENABLES PRECISE REGISTRATION OF HISTOLOGY TO 3D IMAGES. THIRD, THE USE OF LIPIDOMICS AND PROTEOMICS TO OBTAIN MOLECULAR PROFILING OF AD TISSUE AS WELL AS EXOSOMES -NANOSIZED VESI- CLES RICH IN CARGO (LIPIDS, PROTEINS, RNA) THAT PROVIDE A SNAPSHOT OF CELL PROCESSES AND CELL COMMUNICATION. THE PROJECT AIMS ARE: (1) TO QUANTIFY AD-SPECIFIC MYELIN DEGENERATION IN HIPPOCAMPAL SUBFIELDS AND TRACTS. WE WILL SAXS-TT-SCAN LOW AD, HIGH AD, AND NORMAL AGING HIPPOCAMPAL SPECIMENS, SEGMENT THEIR SUBFIELDS AND TRACTS IN DETAIL, AND TEST IF VULNERABLE TRACTS AND ASSOCIATED SUBFIELDS SUCH AS THE PERFORANT PATHWAY, ENTO- RHINAL CORTEX, DENTATE GYRUS, CA1, CA3 HAVE AD-SPECIFIC MYELINATION. (2) TO DETERMINE THE SPATIAL RELATIONSHIP BETWEEN MYELIN DEGENERATION AND AMYLOID, TAU, OR INFLAMMATION. WE WILL SECTION AIM 1 SPECIMENS, STAIN FOR AMYLOID, TAU, AND MICROGLIA AND REGISTER HISTOLOGY WITH IMAGING USING OUR SERIAL BLOCKFACE PIPELINE. THIS WILL AL- LOW CORRELATING MYELIN WITH STAINS AND PROVIDE EVIDENCE TOWARDS TWO LITERATURE-SUPPORTED HYPOTHESES: THAT MYE- LIN DEGENERATION OVERWHELMS MICROGLIA INHIBITING AMYLOID CLEARANCE, OR THAT TAU PROPAGATES VIA DEMYELINATING TRACTS. (3) TO DETECT AD-SPECIFIC MOLECULAR/EXOSOMAL MARKERS LINKED TO MACROSCOPIC MYELIN DEGENERATION. LIPID DYSREGULATION IS EXTENSIVE IN AD, BUT ITS ORIGIN IS NOT KNOWN. WE WILL TEST IF IT IS DRIVEN BY LIPID-RICH MYELIN, BY COMBINING MYELIN LEVELS WITH LIPIDOMICS/PROTEOMICS ANALYSIS TO QUANTIFY MYELIN LIPIDS AND PROTEINS IN TISSUE AND EXOSOMES, AND TEST IF SPECIFIC LIPIDS AND PROTEINS PARALLEL MACROSCOPIC MYELIN LOSS. INTRODUCING AD EXOSOMES TO OLIGODENDROCYTE CULTURES AND PERFORMING LIPIDOMICS/PROTEOMICS ON THE CELLS CAN SHOW IF IN VIVO MYELIN CHANGES ARE REFLECTED IN VITRO, SUGGESTING A POTENTIAL DISEASE PROPAGATION MECHANISM. THIS STUDY WILL COMBINE MACROSCOPIC WITH MOLECULAR ANALYSES TO PROVIDE A MULTI-FACETED VIEW OF MYELIN PATHOLOGY IN AD.

Posted 4/18/24, 12:00 AM